Selective targeting of myoblast fusogenic signaling and differentiation-arrest antagonizes rhabdomyosarcoma cells

Valerie A. Granados, Usha Avirneni-Vadlamudi, Pooja Dalal, Samuel R. Scarborough, Kathleen A. Galindo, Priya Mahajan, Rene L Galindo

Research output: Contribution to journalArticle

Abstract

Rhabdomyosarcoma (RMS) is an aggressive soft tissue malignancy comprised histologically of skeletal muscle lineage precursors that fail to exit the cell cycle and fuse into differentiated syncytial muscle-for which the underlying pathogenetic mechanisms remain unclear. In contrast to myogenic transcription factor signaling, the molecular machinery that orchestrates the discrete process of myoblast fusion in mammals is poorly understood and unexplored in RMS. The fusogenic machinery in Drosophila, however, is understood in much greater detail, where myoblasts are divided into two distinct pools, founder cells (FC) and fusion competent myoblasts (fcm). Fusion is heterotypic and only occurs between FCs and fcms. Here, we interrogated a comprehensive RNA-sequencing database and found that human RMS diffusely demonstrates an FC lineage gene signature, revealing that RMS is a disease of FC lineage rhabdomyoblasts. We next exploited our Drosophila RMS-related model to isolate druggable FC-specific fusogenic elements underlying RMS, which uncovered the EGFR pathway. Using RMS cells, we showed that EGFR inhibitors successfully antagonized RMS RD cells, whereas other cell lines were resistant. EGFR inhibitor-sensitive cells exhibited decreased activation of the EGFR intracellular effector Akt, whereas Akt activity remained unchanged in inhibitorresistant cells. We then demonstrated that Akt inhibition antagonizes RMS-including RMS resistant to EGFR inhibition- and that sustained activity of the Akt1 isoform preferentially blocks rhabdomyoblast differentiation potential in cell culture and in vivo. These findings point towards selective targeting of fusion- and differentiation-arrest via Akt as a broad RMS therapeutic vulnerability.

Original languageEnglish (US)
Pages (from-to)4585-4591
Number of pages7
JournalCancer Research
Volume79
Issue number18
DOIs
StatePublished - Sep 15 2019

Fingerprint

Rhabdomyosarcoma
Myoblasts
Cell Lineage
Drosophila
RNA Sequence Analysis
Cell Fusion
Nucleic Acid Databases
Mammals
Cell Cycle
Protein Isoforms
Skeletal Muscle
Transcription Factors
Cell Culture Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Granados, V. A., Avirneni-Vadlamudi, U., Dalal, P., Scarborough, S. R., Galindo, K. A., Mahajan, P., & Galindo, R. L. (2019). Selective targeting of myoblast fusogenic signaling and differentiation-arrest antagonizes rhabdomyosarcoma cells. Cancer Research, 79(18), 4585-4591. https://doi.org/10.1158/0008-5472.CAN-18-2096

Selective targeting of myoblast fusogenic signaling and differentiation-arrest antagonizes rhabdomyosarcoma cells. / Granados, Valerie A.; Avirneni-Vadlamudi, Usha; Dalal, Pooja; Scarborough, Samuel R.; Galindo, Kathleen A.; Mahajan, Priya; Galindo, Rene L.

In: Cancer Research, Vol. 79, No. 18, 15.09.2019, p. 4585-4591.

Research output: Contribution to journalArticle

Granados, VA, Avirneni-Vadlamudi, U, Dalal, P, Scarborough, SR, Galindo, KA, Mahajan, P & Galindo, RL 2019, 'Selective targeting of myoblast fusogenic signaling and differentiation-arrest antagonizes rhabdomyosarcoma cells', Cancer Research, vol. 79, no. 18, pp. 4585-4591. https://doi.org/10.1158/0008-5472.CAN-18-2096
Granados VA, Avirneni-Vadlamudi U, Dalal P, Scarborough SR, Galindo KA, Mahajan P et al. Selective targeting of myoblast fusogenic signaling and differentiation-arrest antagonizes rhabdomyosarcoma cells. Cancer Research. 2019 Sep 15;79(18):4585-4591. https://doi.org/10.1158/0008-5472.CAN-18-2096
Granados, Valerie A. ; Avirneni-Vadlamudi, Usha ; Dalal, Pooja ; Scarborough, Samuel R. ; Galindo, Kathleen A. ; Mahajan, Priya ; Galindo, Rene L. / Selective targeting of myoblast fusogenic signaling and differentiation-arrest antagonizes rhabdomyosarcoma cells. In: Cancer Research. 2019 ; Vol. 79, No. 18. pp. 4585-4591.
@article{152ad54c211143b1966b812ce1b896dd,
title = "Selective targeting of myoblast fusogenic signaling and differentiation-arrest antagonizes rhabdomyosarcoma cells",
abstract = "Rhabdomyosarcoma (RMS) is an aggressive soft tissue malignancy comprised histologically of skeletal muscle lineage precursors that fail to exit the cell cycle and fuse into differentiated syncytial muscle-for which the underlying pathogenetic mechanisms remain unclear. In contrast to myogenic transcription factor signaling, the molecular machinery that orchestrates the discrete process of myoblast fusion in mammals is poorly understood and unexplored in RMS. The fusogenic machinery in Drosophila, however, is understood in much greater detail, where myoblasts are divided into two distinct pools, founder cells (FC) and fusion competent myoblasts (fcm). Fusion is heterotypic and only occurs between FCs and fcms. Here, we interrogated a comprehensive RNA-sequencing database and found that human RMS diffusely demonstrates an FC lineage gene signature, revealing that RMS is a disease of FC lineage rhabdomyoblasts. We next exploited our Drosophila RMS-related model to isolate druggable FC-specific fusogenic elements underlying RMS, which uncovered the EGFR pathway. Using RMS cells, we showed that EGFR inhibitors successfully antagonized RMS RD cells, whereas other cell lines were resistant. EGFR inhibitor-sensitive cells exhibited decreased activation of the EGFR intracellular effector Akt, whereas Akt activity remained unchanged in inhibitorresistant cells. We then demonstrated that Akt inhibition antagonizes RMS-including RMS resistant to EGFR inhibition- and that sustained activity of the Akt1 isoform preferentially blocks rhabdomyoblast differentiation potential in cell culture and in vivo. These findings point towards selective targeting of fusion- and differentiation-arrest via Akt as a broad RMS therapeutic vulnerability.",
author = "Granados, {Valerie A.} and Usha Avirneni-Vadlamudi and Pooja Dalal and Scarborough, {Samuel R.} and Galindo, {Kathleen A.} and Priya Mahajan and Galindo, {Rene L}",
year = "2019",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-18-2096",
language = "English (US)",
volume = "79",
pages = "4585--4591",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Selective targeting of myoblast fusogenic signaling and differentiation-arrest antagonizes rhabdomyosarcoma cells

AU - Granados, Valerie A.

AU - Avirneni-Vadlamudi, Usha

AU - Dalal, Pooja

AU - Scarborough, Samuel R.

AU - Galindo, Kathleen A.

AU - Mahajan, Priya

AU - Galindo, Rene L

PY - 2019/9/15

Y1 - 2019/9/15

N2 - Rhabdomyosarcoma (RMS) is an aggressive soft tissue malignancy comprised histologically of skeletal muscle lineage precursors that fail to exit the cell cycle and fuse into differentiated syncytial muscle-for which the underlying pathogenetic mechanisms remain unclear. In contrast to myogenic transcription factor signaling, the molecular machinery that orchestrates the discrete process of myoblast fusion in mammals is poorly understood and unexplored in RMS. The fusogenic machinery in Drosophila, however, is understood in much greater detail, where myoblasts are divided into two distinct pools, founder cells (FC) and fusion competent myoblasts (fcm). Fusion is heterotypic and only occurs between FCs and fcms. Here, we interrogated a comprehensive RNA-sequencing database and found that human RMS diffusely demonstrates an FC lineage gene signature, revealing that RMS is a disease of FC lineage rhabdomyoblasts. We next exploited our Drosophila RMS-related model to isolate druggable FC-specific fusogenic elements underlying RMS, which uncovered the EGFR pathway. Using RMS cells, we showed that EGFR inhibitors successfully antagonized RMS RD cells, whereas other cell lines were resistant. EGFR inhibitor-sensitive cells exhibited decreased activation of the EGFR intracellular effector Akt, whereas Akt activity remained unchanged in inhibitorresistant cells. We then demonstrated that Akt inhibition antagonizes RMS-including RMS resistant to EGFR inhibition- and that sustained activity of the Akt1 isoform preferentially blocks rhabdomyoblast differentiation potential in cell culture and in vivo. These findings point towards selective targeting of fusion- and differentiation-arrest via Akt as a broad RMS therapeutic vulnerability.

AB - Rhabdomyosarcoma (RMS) is an aggressive soft tissue malignancy comprised histologically of skeletal muscle lineage precursors that fail to exit the cell cycle and fuse into differentiated syncytial muscle-for which the underlying pathogenetic mechanisms remain unclear. In contrast to myogenic transcription factor signaling, the molecular machinery that orchestrates the discrete process of myoblast fusion in mammals is poorly understood and unexplored in RMS. The fusogenic machinery in Drosophila, however, is understood in much greater detail, where myoblasts are divided into two distinct pools, founder cells (FC) and fusion competent myoblasts (fcm). Fusion is heterotypic and only occurs between FCs and fcms. Here, we interrogated a comprehensive RNA-sequencing database and found that human RMS diffusely demonstrates an FC lineage gene signature, revealing that RMS is a disease of FC lineage rhabdomyoblasts. We next exploited our Drosophila RMS-related model to isolate druggable FC-specific fusogenic elements underlying RMS, which uncovered the EGFR pathway. Using RMS cells, we showed that EGFR inhibitors successfully antagonized RMS RD cells, whereas other cell lines were resistant. EGFR inhibitor-sensitive cells exhibited decreased activation of the EGFR intracellular effector Akt, whereas Akt activity remained unchanged in inhibitorresistant cells. We then demonstrated that Akt inhibition antagonizes RMS-including RMS resistant to EGFR inhibition- and that sustained activity of the Akt1 isoform preferentially blocks rhabdomyoblast differentiation potential in cell culture and in vivo. These findings point towards selective targeting of fusion- and differentiation-arrest via Akt as a broad RMS therapeutic vulnerability.

UR - http://www.scopus.com/inward/record.url?scp=85072234937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072234937&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-2096

DO - 10.1158/0008-5472.CAN-18-2096

M3 - Article

C2 - 31331911

AN - SCOPUS:85072234937

VL - 79

SP - 4585

EP - 4591

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 18

ER -